Free Trial

Galecto (GLTO) Competitors

$0.53
-0.03 (-4.66%)
(As of 12:14 PM ET)

GLTO vs. LMNL, EYEN, PRPH, ALRN, CELU, RMTI, MURA, ANEB, VHAQ, and RLYB

Should you be buying Galecto stock or one of its competitors? The main competitors of Galecto include Liminal BioSciences (LMNL), Eyenovia (EYEN), ProPhase Labs (PRPH), Aileron Therapeutics (ALRN), Celularity (CELU), Rockwell Medical (RMTI), Mural Oncology (MURA), Anebulo Pharmaceuticals (ANEB), Viveon Health Acquisition (VHAQ), and Rallybio (RLYB). These companies are all part of the "pharmaceutical preparations" industry.

Galecto vs.

Liminal BioSciences (NASDAQ:LMNL) and Galecto (NASDAQ:GLTO) are both small-cap medical companies, but which is the superior investment? We will contrast the two businesses based on the strength of their analyst recommendations, institutional ownership, profitability, valuation, dividends, community ranking, earnings, risk and media sentiment.

Liminal BioSciences has higher revenue and earnings than Galecto. Galecto is trading at a lower price-to-earnings ratio than Liminal BioSciences, indicating that it is currently the more affordable of the two stocks.

CompanyGross RevenuePrice/Sales RatioNet IncomeEarnings Per SharePrice/Earnings Ratio
Liminal BioSciences$310K85.00$380K$0.2929.31
GalectoN/AN/A-$38.35M-$1.14-0.47

In the previous week, Galecto had 1 more articles in the media than Liminal BioSciences. MarketBeat recorded 1 mentions for Galecto and 0 mentions for Liminal BioSciences. Galecto's average media sentiment score of 0.00 equaled Liminal BioSciences'average media sentiment score.

Company Overall Sentiment
Liminal BioSciences Neutral
Galecto Neutral

Galecto has a consensus target price of $4.33, suggesting a potential upside of 679.38%. Given Liminal BioSciences' higher probable upside, analysts clearly believe Galecto is more favorable than Liminal BioSciences.

Company Sell Ratings Hold Ratings Buy Ratings Strong Buy Ratings Rating Score
Liminal BioSciences
0 Sell rating(s)
0 Hold rating(s)
0 Buy rating(s)
0 Strong Buy rating(s)
N/A
Galecto
0 Sell rating(s)
4 Hold rating(s)
1 Buy rating(s)
0 Strong Buy rating(s)
2.20

Galecto received 17 more outperform votes than Liminal BioSciences when rated by MarketBeat users. Likewise, 59.62% of users gave Galecto an outperform vote while only 48.28% of users gave Liminal BioSciences an outperform vote.

CompanyUnderperformOutperform
Liminal BioSciencesOutperform Votes
14
48.28%
Underperform Votes
15
51.72%
GalectoOutperform Votes
31
59.62%
Underperform Votes
21
40.38%

Liminal BioSciences has a net margin of 248.35% compared to Liminal BioSciences' net margin of 0.00%. Liminal BioSciences' return on equity of -87.11% beat Galecto's return on equity.

Company Net Margins Return on Equity Return on Assets
Liminal BioSciences248.35% -88.44% -64.15%
Galecto N/A -87.11%-68.68%

Liminal BioSciences has a beta of 1.03, suggesting that its stock price is 3% more volatile than the S&P 500. Comparatively, Galecto has a beta of 1.18, suggesting that its stock price is 18% more volatile than the S&P 500.

0.7% of Liminal BioSciences shares are owned by institutional investors. Comparatively, 14.2% of Galecto shares are owned by institutional investors. 2.2% of Liminal BioSciences shares are owned by insiders. Comparatively, 12.1% of Galecto shares are owned by insiders. Strong institutional ownership is an indication that endowments, hedge funds and large money managers believe a company is poised for long-term growth.

Summary

Galecto beats Liminal BioSciences on 9 of the 15 factors compared between the two stocks.

New MarketBeat Followers Over Time

This chart shows the number of new MarketBeat users adding GLTO and its top 5 competitors to their watchlist. Each company is represented with a line over a 90 day period.
Skip Chart

Media Sentiment Over Time

This chart shows the average media sentiment of NASDAQ and its competitors over the past 90 days as caculated by MarketBeat. The averaged score is equivalent to the following: Very Negative Sentiment <= -1.5, Negative Sentiment > -1.5 and <= -0.5, Neutral Sentiment > -0.5 and < 0.5, Positive Sentiment >= 0.5 and < 1.5, and Very Positive Sentiment >= 1.5.
Skip Chart

GLTO vs. The Competition

MetricGalectoPharmaceutical IndustryMedical SectorNASDAQ Exchange
Market Cap$14.64M$6.94B$5.04B$8.47B
Dividend YieldN/A2.85%5.25%3.96%
P/E Ratio-0.479.69111.4314.77
Price / SalesN/A278.942,106.4880.78
Price / CashN/A32.1033.9633.62
Price / Book0.455.934.894.64
Net Income-$38.35M$143.16M$106.77M$214.29M
7 Day Performance-8.63%4.04%112.78%2.59%
1 Month Performance8.54%12.26%124.76%8.39%
1 Year Performance-76.62%-1.75%130.77%3.72%

Galecto Competitors List

CompanyMarketRankShare PriceAnalysts' Price Target1Y Price PerformanceMarket CapRevenueP/E RatioEmployee CountIndicator(s)
LMNL
Liminal BioSciences
0 of 5 stars
0.00 / 5 stars
$8.50
+0.1%
N/A+1.6%$26.35M$310,000.0029.31251
EYEN
Eyenovia
1.1654 of 5 stars
1.17 / 5 stars
$1.11
-5.1%
$10.00
+800.9%
-50.2%$59.80M$8,780.00-1.4857Positive News
Gap Up
PRPH
ProPhase Labs
1.3762 of 5 stars
1.38 / 5 stars
$3.12
-2.8%
$11.00
+252.6%
-55.7%$59.53M$44.38M-2.89113News Coverage
ALRN
Aileron Therapeutics
2.3682 of 5 stars
2.37 / 5 stars
$2.74
-2.1%
$19.00
+593.4%
+53.1%$59.21MN/A-0.8615Gap Up
CELU
Celularity
0 of 5 stars
0.00 / 5 stars
$3.02
-0.3%
N/A-46.4%$58.53M$17.98M0.00220Gap Up
RMTI
Rockwell Medical
3.8846 of 5 stars
3.88 / 5 stars
$1.92
+1.1%
$7.00
+264.6%
-52.4%$58.21M$83.61M-5.33237News Coverage
Positive News
MURA
Mural Oncology
2.9324 of 5 stars
2.93 / 5 stars
$3.43
+0.3%
$14.00
+308.2%
N/A$57.88MN/A0.00119News Coverage
ANEB
Anebulo Pharmaceuticals
2.2164 of 5 stars
2.22 / 5 stars
$2.20
flat
$6.67
+203.0%
-3.9%$57.05MN/A-5.952Positive News
VHAQ
Viveon Health Acquisition
0 of 5 stars
0.00 / 5 stars
$10.00
flat
N/AN/A$56.60MN/A0.00N/A
RLYB
Rallybio
2.4025 of 5 stars
2.40 / 5 stars
$1.34
+3.1%
$12.20
+810.4%
-78.2%$55.54MN/A-0.7130Gap Up

Related Companies and Tools

This page (NASDAQ:GLTO) was last updated on 7/22/2024 by MarketBeat.com Staff

From Our Partners